Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immunogen Inc. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct art units at the USPTO. The company's prosecution efforts involve 5 distinct examiners, which suggests a broad spread of oversight for the current filings.
RODRIGUEZ-GARCIA, VALERIE is the busiest examiner for this portfolio, with 1 pending office action currently assigned. This figure for the busiest examiner indicates that the workload is not concentrated under a single individual. The 5 distinct examiners each handle a portion of the 5 pending office actions currently on record.
The 4 distinct art units involved in these cases show that the Biotechnology & Pharmaceuticals work spans multiple specialized groups. With 5 pending office actions and 5 distinct examiners, the portfolio experiences a variety of examiner perspectives. Practitioners should prepare for interactions across the 4 distinct art units to resolve the 5 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
| DUFFY, BRADLEY | 1 | 54.4% | +46.0% |
| KIM, YUNSOO | 1 | 66.0% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18634736 | ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS | JOHNSON, TIRONE DEREK | — |
| 18146307 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | DUFFY, BRADLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18054076 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | KIM, YUNSOO | 22d |
| 19018232 | CONJUGATION METHODS | RODRIGUEZ-GARCIA, VALERIE | — |
| 18683361 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | BURKETT, DANIEL JOHN | — |
| 18146307 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | DUFFY, BRADLEY | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1624 | 1 |
| 1643 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19018232 | CONJUGATION METHODS | RODRIGUEZ-GARCIA, VALERIE | — | §112Other | Non-Final OA | — | Pending | Jan 13, 2025 |
| 18634736 | ANTI-FOLR1 IMMUNOCONJUGATE REGIMENS | JOHNSON, TIRONE DEREK | 1675 | §102§103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18683361 | IMPROVED METHODS FOR PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | BURKETT, DANIEL JOHN | 1624 | §102DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18146307 | METHODS FOR FORMULATING ANTIBODY DRUG CONJUGATE COMPOSITIONS | DUFFY, BRADLEY | 1643 | §102§103§112 | Non-Final OA | — | Pending | Dec 23, 2022 |
| 18054076 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | KIM, YUNSOO | 1641 | Other | Final Rejection | 22d | Pending | Nov 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunogen Inc. has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Valerie Rodriguez-Garcia has the most, with 1 of Immunogen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
